AstraZeneca-Merck Lynparza gets EMA's positive recommendation
June 01, 2020 at 02:15 AM EDT
Drugmakers AstraZeneca Plc and Merck & Co Inc said on Monday their blockbluster cancer drug, Lynparza, has received positive recommendation from the European Medicines Agency (EMA) as a maintenance treatment for a form of pancreatic cancer.